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background:  Patients with end stage renal disease (ESRD) are at increased risk of complications after trans-venous defibrillators. The 
subcutaneous ICD (S-ICD®) offers an attractive alternative in this population, however, data on the safety and efficacy of the S-ICD in 
dialysis patients is lacking.
Methods:  We reviewed all S-ICD implants at our center and stratified patients based on need for dialysis at the time of implant. The 
combined primary endpoint was incidence of device related complications requiring surgical re-intervention and incidence of defibrillator 
shocks (appropriate & inappropriate). The secondary end point was incidence of death or heart failure (HF) hospitalization.
results:  68 patients underwent SICD implantation (18 on dialysis, 50 without dialysis). Dialysis patients were older (60.3 vs 48.0 years, p 
= 0.004), had lower ejection fraction (24.7 vs. 32.5%, p = 0.042), more likely diabetic (72 vs. 30%, p = 0.004) and less likely to have primary 
electrical disorders (0 vs. 20%, p = 0.05). 75% of the cohort underwent S-ICD implantation for primary prevention and 17% had prior 
trans-venous ICDs, without significant differences between groups. Fewer patients in the dialysis cohort underwent defibrillation threshold 
(DFT) testing at implant (67 vs. 90%, p = 0.06) and among those who were tested, the lowest successful energy was higher in the dialysis 
cohort (70.0 vs. 65.9 J, p = 0.011). The primary endpoint occurred in 10 patients (20%) in the non-dialysis cohort (6 inappropriate shocks, 1 
appropriate shock and 3 infections requiring explant) and 1 patient (5.5%) in the dialysis cohort (appropriate shock) (p = 0.384). There were 
no inappropriate shocks and no infections requiring explant in the dialysis cohort. The secondary endpoint occurred in 7 patients in the non-
dialysis cohort (3 deaths, 4 HF hospitalizations) and 2 patients in the dialysis cohort (1 death, 1 HF hospitalization) (p = 0.484).
Conclusion:  Our data suggest that SICD implantation in dialysis patients is not associated with an excess risk of implant related 
complications or inappropriate shocks. The incidence of other endpoints is also comparable between dialysis and non-dialysis patients.
